9-34514436-G-A
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_012144.4(DNAI1):c.1612G>A(p.Ala538Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000911 in 1,613,946 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000072 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000093 ( 0 hom. )
Consequence
DNAI1
NM_012144.4 missense
NM_012144.4 missense
Scores
7
10
2
Clinical Significance
Conservation
PhyloP100: 9.12
Genes affected
DNAI1 (HGNC:2954): (dynein axonemal intermediate chain 1) This gene encodes a member of the dynein intermediate chain family. The encoded protein is part of the dynein complex in respiratory cilia. The inner- and outer-arm dyneins, which bridge between the doublet microtubules in axonemes, are the force-generating proteins responsible for the sliding movement in axonemes. The intermediate and light chains, thought to form the base of the dynein arm, help mediate attachment and may also participate in regulating dynein activity. Mutations in this gene result in abnormal ciliary ultrastructure and function associated with primary ciliary dyskinesia and Kartagener syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.95
PP5
Variant 9-34514436-G-A is Pathogenic according to our data. Variant chr9-34514436-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 583106.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNAI1 | NM_012144.4 | c.1612G>A | p.Ala538Thr | missense_variant | 17/20 | ENST00000242317.9 | NP_036276.1 | |
DNAI1 | NM_001281428.2 | c.1624G>A | p.Ala542Thr | missense_variant | 17/20 | NP_001268357.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152068Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
11
AN:
152068
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000756 AC: 19AN: 251310Hom.: 0 AF XY: 0.000103 AC XY: 14AN XY: 135832
GnomAD3 exomes
AF:
AC:
19
AN:
251310
Hom.:
AF XY:
AC XY:
14
AN XY:
135832
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000930 AC: 136AN: 1461878Hom.: 0 Cov.: 32 AF XY: 0.0000908 AC XY: 66AN XY: 727240
GnomAD4 exome
AF:
AC:
136
AN:
1461878
Hom.:
Cov.:
32
AF XY:
AC XY:
66
AN XY:
727240
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152068Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74288
GnomAD4 genome
AF:
AC:
11
AN:
152068
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74288
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
9
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Primary ciliary dyskinesia Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 14, 2023 | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 538 of the DNAI1 protein (p.Ala538Thr). This variant is present in population databases (rs368248592, gnomAD 0.01%). This missense change has been observed in individual(s) with primary ciliary dyskinesia (PMID: 16858015, 21143860). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 583106). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on DNAI1 protein function. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 10, 2015 | The p.A538T pathogenic mutation (also known as c.1612G>A), located in coding exon 17 of the DNAI1 gene, results from a G to A substitution at nucleotide position 1612. The alanine at codon 538 is replaced by threonine, an amino acid with some similar properties. This alteration was first reported in two unrelated individuals with symptoms of PCD with a second pathogenic alteration (confirmed in trans in one patient); both patients had outer dynein arm defects identified by ultrastructual analysis (Zariwala MA et al. Am J Respir Crit Care Med. 2006;174(8):858-66). In addition, this alteration was identified in the homozygous state in three families and in conjunction with another pathogenic mutation in an additional two patients, all who had symptoms of PCD and dynein arm defects; authors suggest this alteration may be a Polish founder mutation (Zitkiewicz E et al. Respir Res. 2010;11:174). Based on the supporting evidence, p.A538T is interpreted as a disease-causing mutation. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Likely pathogenic, no assertion criteria provided | literature only | Yale Center for Mendelian Genomics, Yale University | Aug 01, 2018 | - - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University Hospital Muenster | Jul 07, 2022 | ACMG categories: PS4,PM1,PM2,PM3,PP1,PP3,PP5 - |
Kartagener syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 06, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Benign
T;T
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D
MetaSVM
Uncertain
T
MutationAssessor
Uncertain
.;M
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;D
REVEL
Pathogenic
Sift
Uncertain
.;D
Sift4G
Uncertain
D;D
Polyphen
0.98
.;D
Vest4
MutPred
0.82
.;Loss of catalytic residue at A538 (P = 0.1088);
MVP
MPC
0.53
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at